We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
New York Health Care Inc (CE) | USOTC:BBAL | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.00 | 01:00:00 |
x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
New
York
|
11-2636089
|
(State
or other jurisdiction of
|
(I.R.S.
Employer Identification No.)
|
incorporation
or organization)
|
|
1850
McDonald Avenue, Brooklyn, New York
|
11223
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Item
1.
|
|
Financial
Statements.
|
|
September
30,
|
December
31,
|
|||||
|
2007
|
2006
|
|||||
|
(Unaudited)
|
|
|||||
ASSETS
|
|
|
|||||
|
|
|
|||||
Current
assets:
|
|
|
|||||
Cash
and cash equivalents
|
$
|
1,718,635
|
$
|
2,469,789
|
|||
Due
from lending institution
|
-
|
274,934
|
|||||
Accounts
receivable, net of allowance for uncollectible amounts of
|
|||||||
$548,000
and $579,000, respectively
|
8,083,371
|
7,146,973
|
|||||
Unbilled
services
|
102,349
|
112,186
|
|||||
Prepaid
expenses and other current assets
|
68,952
|
227,625
|
|||||
|
|||||||
Total
current assets
|
9,973,307
|
10,231,507
|
|||||
|
|||||||
Property
and equipment, net
|
82,455
|
120,898
|
|||||
Goodwill,
net
|
783,000
|
783,000
|
|||||
Other
intangible assets, net
|
1,413,017
|
1,575,495
|
|||||
Other
assets
|
169,095
|
168,638
|
|||||
|
|||||||
Total
assets
|
$
|
12,420,874
|
$
|
12,879,538
|
|||
|
|||||||
LIABILITIES
AND SHAREHOLDERS' DEFICIENCY
|
|||||||
|
|||||||
Current
liabilities:
|
|||||||
Accrued
payroll
|
$
|
1,019,915
|
$
|
775,808
|
|||
Accounts
payable and accrued expenses
|
5,042,034
|
5,963,589
|
|||||
Income
taxes payable - current
|
39,450
|
-
|
|||||
Due
to HRA
|
8,440,402
|
7,942,757
|
|||||
|
|||||||
Total
current liabilities
|
14,541,801
|
14,682,154
|
|||||
|
|||||||
Commitment
and contingencies
|
|||||||
|
|||||||
Shareholders'
(deficiency):
|
|||||||
Preferred
stock, $.01 par value, 5,000,000 shares authorized;
|
|||||||
Class
A Preferred, 590,375 shares issued, none outstanding
|
|||||||
Common
stock, $.01 par value, 100,000,000 shares authorized;
|
|||||||
33,536,767
shares issued and 33,532,722 outstanding at September 30,
2007
|
|||||||
33,536,767
shares issued and 33,782,722 outstanding as of December 31,
2006
|
335,368
|
335,368
|
|||||
Additional
paid-in capital
|
37,174,185
|
37,149,685
|
|||||
Common
stock and options to be issued
|
774,220
|
774,220
|
|||||
Accumulated
deficit
|
(40,395,227
|
)
|
(40,052,416
|
)
|
|||
Less:
Treasury stock (4,045 common shares at cost)
|
(9,473
|
)
|
(9,473
|
)
|
|||
|
|||||||
Total
shareholders' (deficiency)
|
(2,120,927
|
)
|
(1,802,616
|
)
|
|||
|
|||||||
Total
liabilities and shareholders' (deficiency)
|
$
|
12,420,874
|
$
|
12,879,538
|
|
||||||||||
NEW
YORK HEALTH CARE, INC. AND SUBSIDIARIES
|
||||||||||
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
||||||||||
(UNAUDITED)
|
|
For
The Three Months Ended September 30,
|
For
The Nine Months Ended September 30,
|
|||||||||||
|
2007
|
2006
|
2007
|
2006
|
|||||||||
|
|
|
|
|
|||||||||
Net
patient service revenue
|
$
|
10,773,937
|
$
|
11,095,345
|
$
|
32,760,415
|
$
|
34,080,229
|
|||||
|
|||||||||||||
Expenses:
|
|||||||||||||
Professional
care of patients
|
8,883,411
|
9,208,649
|
27,003,984
|
27,752,702
|
|||||||||
Operating
income before other operating expenses
|
1,890,526
|
1,886,696
|
5,756,431
|
6,327,527
|
|||||||||
|
|||||||||||||
Other
operating expenses:
|
|||||||||||||
General
and administrative
|
1,653,500
|
2,269,828
|
5,232,241
|
6,551,861
|
|||||||||
Product
development
|
94,547
|
517,294
|
565,801
|
1,861,783
|
|||||||||
Depreciation
and amortization
|
99,410
|
171,080
|
295,849
|
501,448
|
|||||||||
|
|||||||||||||
Total
other operating expenses
|
1,847,457
|
2,958,202
|
6,093,891
|
8,915,092
|
|||||||||
|
|||||||||||||
Operating
income (loss)
|
43,069
|
(1,071,506
|
)
|
(337,460
|
)
|
(2,587,565
|
)
|
||||||
|
|||||||||||||
Other
income (expenses):
|
|||||||||||||
Interest
income
|
17,027
|
42,986
|
56,371
|
133,261
|
|||||||||
Interest
expense
|
(5,061
|
)
|
-
|
(10,642
|
)
|
(7,863
|
)
|
||||||
|
|||||||||||||
Other
income, net
|
11,966
|
42,986
|
45,729
|
125,398
|
|||||||||
|
|||||||||||||
Income
(loss) before provision for income taxes
|
55,035
|
(1,028,520
|
)
|
(291,731
|
)
|
(2,462,167
|
)
|
||||||
|
|||||||||||||
Provision
for income taxes - current
|
-
|
-
|
51,080
|
35,268
|
|||||||||
|
|||||||||||||
Net
income (loss)
|
$
|
55,035
|
$
|
(1,028,520
|
)
|
$
|
(342,811
|
)
|
$
|
(2,497,435
|
)
|
||
|
|||||||||||||
Basic
income (loss) per share:
|
|||||||||||||
Net
income (loss) per share:
|
$
|
0.00
|
($0.03
|
)
|
($0.01
|
)
|
($0.08
|
)
|
|||||
|
|||||||||||||
Basic
weighted average shares outstanding
|
33,536,767
|
33,408,546
|
33,536,767
|
33,291,546
|
|||||||||
|
|||||||||||||
Diluted
income (loss) per share:
|
|||||||||||||
Net
income (loss) per share:
|
$
|
0.00
|
($0.03
|
)
|
($0.01
|
)
|
($0.08
|
)
|
|||||
|
|||||||||||||
Diluted
weighted average shares outstanding
|
33,536,767
|
33,408,546
|
33,536,767
|
33,291,546
|
NEW
YORK HEALTH CARE, INC. AND SUBSIDIARIES
|
|||||
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|||||
(UNAUDITED)
|
For
The Nine Months Ended
September 30, |
|||||||
|
2007
|
2006
|
|||||
Cash
flows from operating activities:
|
|
|
|||||
|
|
|
|||||
Net
(loss)
|
$
|
(342,811
|
)
|
$
|
(2,497,435
|
)
|
|
|
|||||||
Adjustments
to reconcile net (loss) to net cash
|
|||||||
used
in operating activities (excluding the effect of
disposition)
|
|||||||
Stock-based
compensation
|
24,500
|
269,404
|
|||||
Depreciation
and amortization
|
295,849
|
501,448
|
|||||
Loss
on abandonment of property and equipment
|
5,653
|
-
|
|||||
Recovery
of bad debts
|
(31,056
|
)
|
-
|
||||
|
|||||||
Changes
in operating assets and liabilities
|
|||||||
(Increase)
decrease in accounts receivable
|
|||||||
and
unbilled services
|
(895,505
|
)
|
11,458
|
||||
Decrease
in due from lending institution
|
274,934
|
68,672
|
|||||
Decrease
(increase) in prepaid expenses and other current assets
|
158,673
|
(301,160
|
)
|
||||
(Increase)
in other assets
|
(457
|
)
|
(77,655
|
)
|
|||
Increase
in accrued payroll
|
244,107
|
244,836
|
|||||
(Decrease)
increase in accounts payable and
|
|||||||
accrued
expenses
|
(921,555
|
)
|
(283,327
|
)
|
|||
Increase
in income taxes payable - current
|
39,450
|
-
|
|||||
Increase
in due to HRA
|
497,645
|
173,425
|
|||||
|
|||||||
Net
cash used in operating activities
|
(650,573
|
)
|
(1,890,334
|
)
|
|||
|
|||||||
Cash
flows from investing activities:
|
|||||||
Acquisition
of property and equipment
|
-
|
(43,371
|
)
|
||||
Acquisition
of intangible assets
|
(100,581
|
)
|
(283,505
|
)
|
|||
|
|||||||
Net
cash used in investing activities
|
(100,581
|
)
|
(326,876
|
)
|
|||
|
|||||||
Cash
flows from financing activities:
|
|||||||
Net
proceeds from issuance of common stock and warrants
|
-
|
2,500
|
|||||
|
|||||||
Net
(decrease) in cash and cash equivalents
|
(751,154
|
)
|
(2,214,710
|
)
|
|||
|
|||||||
Cash
and cash equivalents at beginning of period
|
2,469,789
|
5,522,088
|
|||||
|
|||||||
Cash
and cash equivalents at end of period
|
$
|
1,718,635
|
$
|
3,307,378
|
|
September
30, 2007
|
||||||||||||
|
Gross
Carrying Cost
|
Accumulated
Amortization |
Net
Carryng Cost
|
Estimated
Useful
Life in Years |
|||||||||
|
|
|
|
|
|||||||||
Intellectual
Property
|
$
|
2,036,500
|
$
|
1,255,795
|
$
|
780,705
|
10
|
||||||
Patents/trademarks
|
875,842
|
259,301
|
616,541
|
10
|
|||||||||
Customer
base
|
316,000
|
300,229
|
15,771
|
5
|
|||||||||
|
$
|
3,228,342
|
$
|
1,815,325
|
$
|
1,413,017
|
|||||||
|
|||||||||||||
|
|||||||||||||
|
December
31, 2006
|
||||||||||||
|
Gross
Carrying Cost
|
Accumulated
Amortization
|
Net
Carryng Cost
|
Estimated
Useful
Life in Years |
|||||||||
|
|||||||||||||
Intellectual
Property
|
$
|
2,036,500
|
$
|
1,103,053
|
$
|
933,447
|
10
|
||||||
Patents/trademarks
|
775,260
|
196,296
|
578,964
|
10
|
|||||||||
Customer
base
|
316,000
|
252,916
|
63,084
|
5
|
|||||||||
|
$
|
3,127,760
|
$
|
1,552,265
|
$
|
1,575,495
|
|
September
30, 2007
|
December
31, 2006
|
|||||
Accounts
payable
|
$
|
406,336
|
$
|
561,445
|
|||
Accrued
expenses
|
1,347,229
|
765,150
|
|||||
Accrued
settlement per consulting agreement
|
1,131,100
|
1,131,100
|
|||||
Accrued
employee benefits
|
2,157,369
|
3,505,894
|
|||||
|
$
|
5,042,034
|
$
|
5,963,589
|
Grant
Date
|
Number
of Options
|
Exercise
Price
|
Expiration
Term
|
|||||||
February
28, 2007
|
50,000
|
$
|
0.13
|
5
yrs
|
||||||
August
20, 2007
|
225,000
|
$
|
0.15
|
10
yrs
|
For
the Three
Months Ended September 30, 2007 |
For
the Nine
Month Ended September 30, 2007 |
||
|
|
|
|
Risk
free interest rate
|
4.64%
|
|
4.64%
to 4.81%
|
Expected
volatility of common stock
|
183%
|
|
183%
to 371%
|
Dividend
yield
|
0%
|
|
0%
|
Expected
option term
|
10
yrs
|
|
10
yrs
|
|
Shares
Under
Options/ Warrants |
Weighted
Average
Exercise Price |
|||||
Balance
at January 1,2007
|
8,996,212
|
$
|
0.93
|
||||
|
|||||||
Options
granted
|
275,000
|
0.14
|
|||||
Options
cancelled/expired
|
(389,166
|
)
|
0.82
|
||||
Options
exercised
|
-
|
-
|
|||||
|
|||||||
Balance
at September 30,2007
|
8,882,046
|
$
|
0.88
|
||||
|
|||||||
Options
eligible for exercise at September 30,2007
|
8,882,046
|
$
|
0.88
|
Options/Warrants
Outstanding
|
Options/Warrants
Exercisable
|
|||||||||||||||
Range
of Exercise Price
|
Options
Warrants Outstanding
|
Weighted
Average Remaining Contractual Life
|
Weighted
Average Exercise Price
|
Options
Warrants Exercisable
|
Weighted
Average Options Warrants Exercisable
|
|||||||||||
|
|
|
|
|
|
|||||||||||
$3.69
|
100,000
|
0.96
|
$
|
3.69
|
100,000
|
$
|
3.69
|
|||||||||
$3.22-3.47
|
48,387
|
0.25
|
3.31
|
48,387
|
$
|
3.31
|
||||||||||
$3.14
|
160,000
|
5.44
|
3.14
|
160,000
|
$
|
3.14
|
||||||||||
$2.55
|
75,333
|
0.67
|
2.55
|
75,333
|
$
|
2.55
|
||||||||||
$2.44
|
6,667
|
0.67
|
2.44
|
6,667
|
$
|
2.44
|
||||||||||
$1.50
|
51,333
|
1.23
|
1.50
|
51,333
|
$
|
1.50
|
||||||||||
$1.21
|
150,000
|
2.92
|
1.21
|
150,000
|
$
|
1.21
|
||||||||||
$1.21
|
50,000
|
3.26
|
1.21
|
50,000
|
$
|
1.21
|
||||||||||
$1.20
|
80,000
|
2.92
|
1.20
|
80,000
|
$
|
1.20
|
||||||||||
$1.00
|
200,000
|
3.67
|
1.00
|
200,000
|
$
|
1.00
|
||||||||||
$0.97
|
66,667
|
2.12
|
0.97
|
66,667
|
$
|
0.97
|
||||||||||
$0.89
|
133,333
|
3.26
|
0.92
|
133,333
|
$
|
0.92
|
||||||||||
$0.84
|
50,000
|
7.68
|
0.84
|
50,000
|
$
|
0.84
|
||||||||||
$0.78
|
5,726,993
|
2.40
|
0.78
|
5,726,993
|
$
|
0.78
|
||||||||||
$0.78
|
30,000
|
3.51
|
0.78
|
30,000
|
$
|
0.78
|
||||||||||
$0.78
|
1,100,000
|
2.43
|
0.78
|
1,100,000
|
$
|
0.78
|
||||||||||
$0.75
|
133,333
|
2.83
|
0.75
|
133,333
|
$
|
0.75
|
||||||||||
$0.75
|
200,000
|
3.02
|
0.75
|
200,000
|
$
|
0.75
|
||||||||||
$0.60
|
20,000
|
9.08
|
0.60
|
20,000
|
$
|
0.60
|
||||||||||
$0.37
|
225,000
|
4.22
|
0.37
|
225,000
|
$
|
0.37
|
||||||||||
$0.13
|
50,000
|
4.42
|
0.13
|
50,000
|
$
|
0.13
|
||||||||||
$0.15
|
225,000
|
9.65
|
0.15
|
225,000
|
$
|
0.15
|
||||||||||
|
8,882,046
|
2.52
|
$
|
0.88
|
8,882,046
|
$
|
0.88
|
|
For
the Nine Months Ended September 30
|
||||||
|
2007
|
2006
|
|||||
|
|
|
|||||
Supplemental
cash flow disclosures:
|
|
|
|||||
|
|
|
|||||
Cash
paid during the period for:
|
|
|
|||||
|
|
|
|||||
Interest
|
$
|
10,642
|
$
|
7,863
|
|||
|
|||||||
Income
taxes
|
$
|
11,630
|
$
|
35,268
|
|
New
York
|
Bio-
|
Total
|
|||||||
|
Health
Care
|
Balance
|
Consolidated
|
|||||||
|
|
|
|
|||||||
Nine
Months Ended September 30, 2007
|
|
|
|
|||||||
Revenue:
|
|
|
|
|||||||
Net
patient service revenue
|
$
|
32,760,415
|
$
|
-
|
$
|
32,760,415
|
||||
Sales
|
-
|
-
|
-
|
|||||||
Total
revenue
|
$
|
32,760,415
|
$
|
-
|
$
|
32,760,415
|
||||
|
||||||||||
Net
income (loss)
|
$
|
1,290,035
|
$
|
(1,632,846
|
)
|
$
|
(342,811
|
)
|
||
|
||||||||||
Total
assets
|
$
|
10,939,847
|
$
|
1,481,027
|
$
|
12,420,874
|
||||
|
||||||||||
|
||||||||||
Nine
Months Ended September 30, 2006
|
||||||||||
Revenue:
|
||||||||||
Net
patient service revenue
|
$
|
34,080,229
|
$
|
-
|
$
|
34,080,229
|
||||
Sales
|
-
|
-
|
-
|
|||||||
Total
revenue
|
$
|
34,080,229
|
$
|
-
|
$
|
34,080,229
|
||||
|
||||||||||
Net
income (loss)
|
$
|
1,250,696
|
$
|
(3,748,131
|
)
|
$
|
(2,497,435
|
)
|
||
|
||||||||||
Total
assets
|
$
|
12,288,203
|
$
|
2,910,277
|
$
|
15,198,480
|
||||
|
||||||||||
|
||||||||||
Three
Months Ended September 30, 2007
|
||||||||||
Revenue:
|
||||||||||
Net
patient service revenue
|
$
|
10,773,937
|
$
|
-
|
$
|
10,773,937
|
||||
Sales
|
-
|
-
|
-
|
|||||||
Total
revenue
|
$
|
10,773,937
|
$
|
-
|
$
|
10,773,937
|
||||
|
||||||||||
Net
income (loss)
|
$
|
662,407
|
$
|
(607,372
|
)
|
$
|
55,035
|
|||
|
||||||||||
|
||||||||||
Three
Months Ended September 30, 2006
|
||||||||||
Revenue:
|
||||||||||
Net
patient service revenue
|
$
|
11,095,345
|
$
|
-
|
$
|
11,095,345
|
||||
Sales
|
-
|
-
|
-
|
|||||||
Total
revenue
|
$
|
11,095,345
|
$
|
-
|
$
|
11,095,345
|
||||
|
||||||||||
Net
income (loss)
|
$
|
126,350
|
$
|
(1,154,870
|
)
|
$
|
(1,028,520
|
)
|
Three
Months Ended
September 30, 2007 |
Three
Months Ended
September 30, 2006 |
||||||||||||||||||
BioBalance
|
Healthcare
|
BioBalance
|
Healthcare
|
Total
|
|||||||||||||||
|
Segment
|
Segment
|
Total
|
Segment
|
Segment
|
|
|||||||||||||
Revenues
|
$
|
-
|
$
|
10,773,937
|
$
|
10,773,937
|
$
|
-
|
$
|
11,095,345
|
$
|
11,095,345
|
|||||||
|
|||||||||||||||||||
Cost
of patient care
|
-
|
8,883,411
|
8,883,411
|
-
|
9,208,649
|
9,208,649
|
|||||||||||||
|
|||||||||||||||||||
SG&A
|
512,827
|
1,240,083
|
1,752,910
|
638,225
|
1,802,683
|
2,440,908
|
|||||||||||||
|
|||||||||||||||||||
Product
Development
|
94,547
|
-
|
94,547
|
517,294
|
--
|
517,294
|
|||||||||||||
|
|||||||||||||||||||
Net
(loss) income
|
$
|
(607,372
|
)
|
$
|
662,407
|
$
|
55,035
|
$
|
(1,154,870
|
)
|
$
|
126,350
|
$
|
(1,028,520
|
)
|
Nine
Months Ended
September 30, 2007 |
Nine
Months Ended
September
30, 2006
|
||||||||||||||||||
BioBalance
|
Healthcare
|
BioBalance
|
Healthcare
|
Total
|
|||||||||||||||
|
Segment
|
Segment
|
Total
|
Segment
|
Segment
|
|
|||||||||||||
Revenues
|
$
|
-
|
$
|
32,760,415
|
$
|
32,760,415
|
$
|
-
|
$
|
34,080,229
|
$
|
34,080,229
|
|||||||
|
|||||||||||||||||||
Cost
of patient care
|
-
|
27,003,984
|
27,003,984
|
-
|
27,752,702
|
27,752,702
|
|||||||||||||
|
|||||||||||||||||||
SG&A
|
1,067,113
|
4,460,977
|
5,528,090
|
1,883,728
|
5,169,581
|
7,053,309
|
|||||||||||||
|
|||||||||||||||||||
Product
Development
|
565,801
|
-
|
565,801
|
1,861,783
|
-
|
1,861,783
|
|||||||||||||
|
|||||||||||||||||||
Net
(loss) income
|
$
|
(1,632,846
|
)
|
$
|
1,290,035
|
$
|
(342,811
|
)
|
$
|
(3,748,131
|
)
|
$
|
1,250,696
|
$
|
(2,497,435
|
)
|
|
Payment
due by period
|
|||||||||||||||
|
|
Less
than
|
|
|
More
than
|
|||||||||||
Contractual
Obligations
|
Total
|
1
year
|
2
years
|
3-5
years
|
5
years
|
|||||||||||
Long-term
debt obligations
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Capital
lease obligations
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Operating
lease obligations*
|
836,000
|
300,000
|
268,000
|
268,000
|
-
|
|||||||||||
Purchase
obligations
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Total
|
$
|
836,000
|
$
|
300,000
|
$
|
268,000
|
$
|
268,000
|
$
|
-
|
*
|
These
leases also generally contain provisions allowing rental obligations
to be
accelerated upon default in the payment of rent or the performance
of
other lease obligations. These leases generally contain provisions
for
additional rent based upon increases in real estate taxes and other
cost
escalations.
|
(a)
|
Exhibits
|
|
Exhibit
|
|
|
No.
|
|
Description
|
|
|
|
31.1
|
|
Certification
of the Principal Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
|
|
31.2
|
|
Certification
of the Principal Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
|
|
32.1
|
|
Certification
of the Chief Executive Officer pursuant to 18 U.S.C.
Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
|
|
|
|
32.2
|
|
Certification
of the Principal Financial Officer pursuant to 18 U.S.C.
Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
|
NEW
YORK HEALTH CARE, INC.
|
||
|
|
|
November
13, 2007
|
By: | /s/ Murry Englard |
Name: Murry Englard |
||
Title:
Chief Executive Officer
|
November
13, 2007
|
By: | /s/ Stewart W. Robinson |
Name: Stewart W. Robinson |
||
Title:
Chief Financial Officer
|
Exhibit
|
|
|
No.
|
|
Description
|
|
|
|
31.1
|
|
Certification
of the Principal Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
|
|
31.2
|
|
Certification
of the Principal Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
|
|
32.1
|
|
Certification
of the Chief Executive Officer pursuant to 18 U.S.C.
Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
|
|
|
|
32.2
|
|
Certification
of the Principal Financial Officer pursuant to 18 U.S.C.
Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
|
1 Year New York Health Care (CE) Chart |
1 Month New York Health Care (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions